未知股票 NEXI 深 沪
已收盘
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 --
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 139.47万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 2.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis
FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis Immix Biopharma Inc. has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its therapy NXC-201, intended for the treatment of relapsed/refractory AL Amyloidosis. T
01-28 21:45
SCYNEXIS Showcases Potent Antifungal Activity of SCY-247 Against Drug-Resistant Fungi at IMARI Conference
SCYNEXIS Showcases Potent Antifungal Activity of SCY-247 Against Drug-Resistant Fungi at IMARI Conference SCYNEXIS Inc. has announced upcoming presentations on its second-generation fungerp drug candidate, SCY-247, highlighting its potent antifungal activity against drug-resistant fungi. The data, w
01-28 21:02
FDA Grants QIDP and Fast Track Designations to SCYNEXIS for SCY-247
FDA Grants QIDP and Fast Track Designations to SCYNEXIS for SCY-247 SCYNEXIS Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to SCY-247, its second-generation triterpenoid antifungal therapy. The QIDP
01-21 21:02
BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247
BRIEF-SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247 Jan 21 (Reuters) - SCYNEXIS Inc SCYX.O : SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247 SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES
01-21 21:01
日本贸易大臣赤泽亮正：要求1.8万亿日元来支持NEXI对美国的投资
日本贸易大臣赤泽亮正表示，日本经济产业省要求在2026财年发行1.78万亿日元（114亿美元）的特别债券，以帮助日本贸易保险机构（NEXI）支持日本对美国的...
2025-12-23 15:50
BUZZ-MS looks for idiosyncratic stories among EU software & services in 2025
** Laying out its 2025 outlook on European software and services names, Morgan Stanley says that similarly to last year economic backdrop is uncertain while IT spending remains subdued ** In such set-...
2025-01-14 18:44
美股牛股 | QS飙升30%，拟与大众汽车大幅提高固态电池的产量；Methode Electronics涨45%
QuantumScape飙升30%，拟与大众汽车大幅提高固态电池的产量；优于预期的业绩提振了市场信心，Methode Electronics涨45%>>
2024-07-12 19:35
Immix Biopharma doses first patient in U.S. AL amyloidosis trial
Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201. The company added that the timing of the milestone was in-line with i...
2024-07-09 02:04
Nexity Ends Joint Shareholder Action, Maintains Support
NEXITY (FR:NXI) has released an update. Nexity has announced the termination of...
2024-07-02 14:16
Immix Biopharma Reports NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data In ASGCT 2024 Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of
2024-05-10 21:36
